ECO Animal Health Group Past Earnings Performance
Past criteria checks 0/6
ECO Animal Health Group's earnings have been declining at an average annual rate of -43.8%, while the Pharmaceuticals industry saw earnings declining at 0.9% annually. Revenues have been growing at an average rate of 5.4% per year.
Key information
-43.8%
Earnings growth rate
-44.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 5.4% |
| Return on equity | -0.2% |
| Net Margin | -1.8% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
ECO Animal Health Group plc (LON:EAH) Soars 28% But It's A Story Of Risk Vs Reward
Apr 27
ECO Animal Health Group plc (LON:EAH) Shares Could Be 46% Below Their Intrinsic Value Estimate
Apr 10Is There An Opportunity With ECO Animal Health Group plc's (LON:EAH) 38% Undervaluation?
Sep 16Are Investors Undervaluing ECO Animal Health Group plc (LON:EAH) By 44%?
Apr 18An Intrinsic Calculation For ECO Animal Health Group plc (LON:EAH) Suggests It's 38% Undervalued
Dec 22Calculating The Fair Value Of ECO Animal Health Group plc (LON:EAH)
Mar 17ECO Animal Health Group's (LON:EAH) Solid Earnings Have Been Accounted For Conservatively
Dec 02ECO Animal Health Group plc (LON:EAH) Shares Could Be 48% Below Their Intrinsic Value Estimate
Nov 16Are Investors Undervaluing ECO Animal Health Group plc (LON:EAH) By 39%?
Apr 30Analysts Are Betting On ECO Animal Health Group plc (LON:EAH) With A Big Upgrade This Week
Mar 09Investors Who Bought ECO Animal Health Group (LON:EAH) Shares A Year Ago Are Now Up 58%
Mar 06Is ECO Animal Health Group (LON:EAH) Using Too Much Debt?
Feb 08
An Intrinsic Calculation For ECO Animal Health Group plc (LON:EAH) Suggests It's 49% Undervalued
Dec 18Revenue & Expenses BreakdownBeta
How ECO Animal Health Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 88 | -2 | 32 | 5 |
| 30 Jun 23 | 87 | 0 | 30 | 6 |
| 31 Mar 23 | 85 | 1 | 28 | 6 |
| 31 Dec 22 | 82 | 1 | 24 | 7 |
| 30 Sep 22 | 79 | 1 | 23 | 7 |
| 30 Jun 22 | 80 | 0 | 24 | 7 |
| 31 Mar 22 | 82 | -1 | 24 | 8 |
| 31 Dec 21 | 92 | 2 | 25 | 7 |
| 30 Sep 21 | 102 | 4 | 26 | 7 |
| 30 Jun 21 | 104 | 6 | 26 | 8 |
| 31 Mar 21 | 106 | 7 | 26 | 8 |
| 31 Dec 20 | 96 | 7 | 22 | 9 |
| 30 Sep 20 | 86 | 5 | 20 | 9 |
| 30 Jun 20 | 79 | 5 | 18 | 9 |
| 31 Mar 20 | 72 | 4 | 17 | 9 |
| 31 Dec 19 | 69 | 4 | 15 | 8 |
| 30 Sep 19 | 66 | 5 | 12 | 7 |
| 30 Jun 19 | 66 | 6 | 12 | 6 |
| 31 Mar 19 | 67 | 7 | 12 | 6 |
| 31 Dec 18 | 70 | 10 | 15 | 3 |
| 30 Sep 18 | 68 | 9 | 15 | 3 |
| 30 Jun 18 | 68 | 9 | 15 | 1 |
| 31 Mar 18 | 67 | 9 | 15 | 0 |
| 31 Dec 17 | 65 | 10 | 14 | 0 |
| 30 Sep 17 | 64 | 11 | 14 | 0 |
| 30 Jun 17 | 63 | 11 | 14 | 0 |
| 31 Mar 17 | 61 | 11 | 15 | 0 |
| 31 Dec 16 | 57 | 9 | 14 | 0 |
| 30 Sep 16 | 53 | 8 | 13 | 0 |
| 30 Jun 16 | 50 | 7 | 12 | 0 |
| 31 Mar 16 | 47 | 6 | 11 | 0 |
| 31 Dec 15 | 45 | 5 | 11 | 0 |
| 30 Sep 15 | 44 | 5 | 10 | 0 |
| 30 Jun 15 | 41 | 4 | 10 | 0 |
| 31 Mar 15 | 39 | 4 | 9 | 0 |
| 31 Dec 14 | 36 | 4 | 9 | 0 |
| 30 Sep 14 | 34 | 4 | 9 | 0 |
| 30 Jun 14 | 33 | 3 | 8 | 0 |
| 31 Mar 14 | 32 | 2 | 8 | 0 |
| 30 Sep 13 | 33 | 3 | 8 | 0 |
| 30 Jun 13 | 31 | 3 | 7 | 0 |
Quality Earnings: EAH is currently unprofitable.
Growing Profit Margin: EAH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EAH is unprofitable, and losses have increased over the past 5 years at a rate of 43.8% per year.
Accelerating Growth: Unable to compare EAH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EAH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: EAH has a negative Return on Equity (-0.25%), as it is currently unprofitable.